Evolving Options for First-line ART and Switch Strategies

Expert-authored slides on selecting among current guideline-recommended initial ART regimens, identifying appropriate switch strategies for patients with virologic suppression on 3-drug ART, including 2-drug oral therapy and long-acting 2-drug injectable therapy options, and new data on effective management of virologic breakthrough with NNRTI-based regimens.
Babafemi Taiwo, MBBS
Program Director
Rajesh T. Gandhi, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 530 KB
Released: September 9, 2021


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Dr William Short and Clinical Care Options (CCO): Data fails to support adding agents to intensify ART, switching ART, or adding IL-2 for patients with suboptimal CD4+ cell counts on suppressive ART

William R. Short, MD, MPH, AAHIVS Released: October 15, 2021

Clinical Care Options (CCO) slides from Nicholas Chamberlain, MD, on investigational HIV PrEP strategies in various stages of development

Nicholas Chamberlain, MD Released: October 15, 2021

Results from a study of impact of 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in people with HIV at IDWeek 2021 reported by Clinical Care Options (CCO)

Released: October 7, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.